Lizaola-Mayo BC, Rodriguez EA. Cytomegalovirus infection after liver transplantation. World J Transplant 2020; 10(7): 183-190 [PMID: 32844094 DOI: 10.5500/wjt.v10.i7.183]
Corresponding Author of This Article
Eduardo A Rodriguez, MD, Assistant Professor, Division of Gastroenterology, Hepatology & Nutrition, University of Utah, 30 N 1900 E, Room 4R118, Salt Lake City, UT 84132, United States. eduardo.rodriguez@hsc.utah.edu
Research Domain of This Article
Transplantation
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Transplant. Jul 29, 2020; 10(7): 183-190 Published online Jul 29, 2020. doi: 10.5500/wjt.v10.i7.183
Cytomegalovirus infection after liver transplantation
Blanca C Lizaola-Mayo, Eduardo A Rodriguez
Blanca C Lizaola-Mayo, Division of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, AZ 85259, United States
Eduardo A Rodriguez, Division of Gastroenterology, Hepatology & Nutrition, University of Utah, Salt Lake City, UT 84132, United States
Author contributions: Lizaola-Mayo BC and Rodriguez EA wrote the paper.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Eduardo A Rodriguez, MD, Assistant Professor, Division of Gastroenterology, Hepatology & Nutrition, University of Utah, 30 N 1900 E, Room 4R118, Salt Lake City, UT 84132, United States. eduardo.rodriguez@hsc.utah.edu
Received: March 24, 2020 Peer-review started: March 24, 2020 First decision: April 22, 2020 Revised: May 28, 2020 Accepted: July 1, 2020 Article in press: July 1, 2020 Published online: July 29, 2020 Processing time: 119 Days and 4 Hours
Abstract
Human cytomegalovirus (CMV) represents the most common opportunistic infection in liver transplant recipients. CMV infections in post liver transplant patients cause significant morbidity and mortality, directly affecting post-transplant outcomes. This review will provide the framework for the surveillance, diagnosis, prophylaxis and treatment of CMV in the liver transplant population.
Core tip: Cytomegalovirus (CMV) is the most common infection in the liver transplant population directly affecting posttransplant outcomes through its direct and indirect effects. The donor and recipient’s CMV serostatus represent the most important factor to determine CMV posttransplant risk, and the need for prophylaxis. Herein, we discuss and summarize the most current CMV preventive, diagnostic, and therapeutic strategies in this vulnerable cohort of patients.
